Literature DB >> 2787358

Liposome-associated tumor necrosis factor retains bioactivity in the presence of neutralizing anti-tumor necrosis factor antibodies.

R J Debs1, N Düzgüneş, E N Brunette, B Fendly, J Patton, R Philip.   

Abstract

Cell-associated TNF-alpha, either bound to its receptor on monocyte membranes or expressed as an integral membrane protein, can exert potent tumor cytolytic activity. We assessed the interaction of TNF with the lipid bilayer membrane system, liposomes, and the effects of membrane association on TNF bioactivity. High levels of TNF can be encapsulated within liposomes. At neutral pH, TNF binds to the surface of preformed liposomes (liposome-associated TNF), but does not partition into the lipid bilayer. TNF appears to bind to negatively charged phospholipid head groups of the outer membrane leaflet. Free TNF, liposome-associated TNF, and liposome-encapsulated TNF display comparable abilities to activate human peripheral blood monocytes and to lyse tumor cells. However, liposome-encapsulated TNF, as well as TNF bound to the outer surface of preformed liposomes, retains bioactivity in the presence of anti-TNF antibodies that neutralize free TNF. The interaction of liposomal TNF with cell surface TNF receptors thus appears to be preserved in the presence of neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787358

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Malaria: a tumour necrosis factor inhibitor from parasitized erythrocytes.

Authors:  N A Sheikh; H N Caro; J Taverne; J H Playfair; T W Rademacher
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

2.  A distinct basic fibroblast growth factor (FGF-2)/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells.

Authors:  M Rusnati; P Dell'Era; C Urbinati; E Tanghetti; M L Massardi; Y Nagamine; E Monti; M Presta
Journal:  Mol Biol Cell       Date:  1996-03       Impact factor: 4.138

Review 3.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.